Stacy Lindborg - 06 Sep 2025 Form 4 Insider Report for Imunon, Inc. (IMNN)

Role: President and CEO, Director
Signature: /s/ Susan Eylward, Attorney-in-Fact for Stacy Lindborg
Issuer symbol: IMNN
Transactions as of: 06 Sep 2025
Net transactions value: $0
Form type: 4
Filing time: 09 Sep 2025, 16:14:01 UTC
Previous filing: 06 Aug 2025
Next filing: 06 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Lindborg Stacy	President and CEO, Director	C/O IMUNON, INC., 997 LENOX DRIVE, SUITE 100, LAWRENCEVILLE	/s/ Susan Eylward, Attorney-in-Fact for Stacy Lindborg	09 Sep 2025	0001813667

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IMNN	Common Stock	Options Exercise	$0	+1,667	+87%	$0.000000	3,584	06 Sep 2025	Direct	F1
holding	IMNN	Common Stock						234	06 Sep 2025	By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IMNN	Restricted Stock	Options Exercise	$0	-1,667	-100%	$0.000000	0	06 Sep 2025	Common Stock	1,667		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Acquisition of common stock resulting from vesting of 100% of the restricted stock granted to Ms. Lindborg on September 6, 2024.
F2	Each restricted stock share represents a contingent right to receive one share of Imunon, Inc.'s common stock.
F3	On September 6, 2024, Ms. Lindborg received restricted stock representing 1,667 shares (as adjusted for the reverse stock split) subject to a one-year vesting schedule, vesting 100% on the first anniversary of the grant date. As restricted stock shares vest, the vested shares are automatically converted to vested common stock on a one-for-one basis on the vesting date.

Remarks:

On July 25, 2025, the Issuer effected a reverse stock split of Issuer Common Stock at a ratio of 1-for-15 (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the shares of Issuer Common Stock, and the exercise price and shares of Issuer Common Stock underlying outstanding equity awards, have been adjusted accordingly versus any amounts previously reported by the Reporting Person. On August 21, 2025, the Issuer paid a 15% stock dividend, 0.15 shares of common stock per share of the Issuer's issued and outstanding shares of common stock, to stockholders of record as of August 7, 2025. As a result of the stock dividend, the shares of Issuer Common Stock have been adjusted accordingly versus any amounts previously reported by the Reporting Person.